1. Generics Bulletin
  2. >>Products
  3. >>Generics

AAM Campaign Aims To Underline Value Of Generics

Social Media Campaign #4GRxANTED Raises Awareness With Videos And Donations

 
• By Dave Wallace

Amid an annual conference at which bolstering the off-patent industry’s reputation was a regular topic of discussion, the AAM has launched a new social media campaign that aims to raise awareness of generics, based around the idea of aspects of life that are taken for granted.

AAM #4GRxANTED Campaign
The AAM’s campaign urges Americans not to take generics and the resulting savings for granted • Source: Association For Accessible Medicines

A new campaign to raise awareness of generics and the benefits they bring has been launched by the US Association for Accessible Medicines under the #4GRxANTED banner.

Introducing the campaign at its Access! 2023 conference in Orlando – at which the need for the generics industry to assert its key role in healthcare and lift its public reputation was acknowledged regularly during session discussions – the AAM said the campaign, details of which are available at a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.